US & World

Pfizer COVID-19 vaccine works well in large-scale “real world” testing –

Pfizer’s COVID-19 vaccine, which has been tested in more than 500,000 people, has been shown to be very effective in preventing serious illness and death even after a single dose.

Wednesday’s published results from a mass vaccination campaign in Israel show the benefits seen in smaller and more limited tests when the vaccine is used much more widely in the general population of different ages and health conditions. It gives a strong sense of security that it has lasted.

The vaccine was effective in preventing serious illness in 92% after two injections and 62% after one injection. Its estimated effect on preventing death was 72% 2-3 weeks after the first shot. This can improve over time as your immunity grows.

It seemed to be as effective for people over 70 as young people.

“This is very encouraging … better than I guessed,” said Dr. Gregory Poland of the Mayo Clinic.

“Even after a single dose, it’s very effective in preventing death,” said Dr. Buddy Kulich of Vanderbilt University.

Neither doctor was involved in the Israeli study, but both are involved in the study of other coronavirus vaccines.

Both doctors also said that the new result is to delay the second shot as the UK is trying, or to extend the limited supply to those who already have COVID-19 as France is doing 2 He said it might encourage consideration of giving a single dose instead of a single dose.

“Rather than seeing 50 million people receive two doses, we want to see 100 million people receive one dose,” Kulich said. “There is a lot of encouragement in a single dose,” according to the Israeli results published by the New England Journal of Medicine.

The vaccine produced by Pfizer and its German partner BioNTech is given twice every three weeks in most countries.

The study was led by researchers at the Clarit Institute in Israel, Ben Gurion University in Negev, and Harvard University in the United States. No vaccine safety was reported, only efficacy was reported, but previous tests did not cause any unexpected problems.

Researchers compared nearly 600,000 people over the age of 16 at Israel’s largest medical institution, fired in December or January, with the same number of people of the same age, gender, and health who were not vaccinated. .. None of the participants had previously tested positive for the virus.

The vaccine was estimated to be 57% effective in preventing COVID-19 symptoms 2-3 weeks after the first dose and 94% more than 1 week after the second dose.

Efficacy was 74% for one shot to prevent hospitalization, 87% for two shots, and 46% and 92% to prevent confirmed infections. Reducing infection gives hope that the vaccine may suppress the spread of the virus, but this type of study cannot determine if that is the case.

There were 41 deaths associated with COVID-19, 32 of whom were unvaccinated.

Overall, this number is often compared to the 95% efficacy after two doses seen in limited trials that led US regulators to approve emergency use of the vaccine. He added that how much benefit a single dose can provide is a big issue, and “and now we have some data” to help inform the discussion.

“Perhaps the right thing to do here to protect the most people is … give everyone a single dose as soon as possible. I think it’s a very acceptable strategy to consider,” Poland said. Said.

Israel currently vaccinates almost half of its population. The results also give insight into how well the vaccine works against it, as the new variant of the virus, first identified in the United Kingdom, became the predominant strain in Israel during the study.

Earlier this week, two UK studies suggested that even after a single dose of a Pfizer vaccine or a vaccine different from AstraZeneca, it would work. The UK has postponed the second shot from the first shot up to 12 weeks to give more people some protection.

___

The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.

Pfizer COVID-19 vaccine works well in large-scale “real world” testing –

Source link Pfizer COVID-19 vaccine works well in large-scale “real world” testing –

Related Articles

Back to top button